UroGen Pharma (NASDAQ:URGN) Earns "Buy" Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of UroGen Pharma (NASDAQ:URGN - Free Report) in a report issued on Monday morning,Benzinga reports. The firm currently has a $25.00 target price on the stock.

URGN has been the subject of several other research reports. LADENBURG THALM/SH SH assumed coverage on shares of UroGen Pharma in a research report on Wednesday, February 19th. They issued a "buy" rating and a $31.00 price target for the company. HC Wainwright restated a "buy" rating and set a $64.00 target price on shares of UroGen Pharma in a report on Tuesday, February 25th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $38.20.

UroGen Pharma Trading Up 0.7 %

Shares of NASDAQ:URGN traded up $0.08 during trading on Monday, reaching $10.90. 222,570 shares of the company were exchanged, compared to its average volume of 377,910. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. The firm has a market capitalization of $255.65 million, a PE ratio of -3.46 and a beta of 1.12. The business's fifty day simple moving average is $10.45 and its 200-day simple moving average is $11.70. UroGen Pharma has a 12-month low of $9.03 and a 12-month high of $20.70.

Remove Ads

UroGen Pharma (NASDAQ:URGN - Get Free Report) last posted its quarterly earnings results on Monday, March 10th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.11). The firm had revenue of $24.57 million during the quarter, compared to analyst estimates of $25.25 million. On average, research analysts anticipate that UroGen Pharma will post -3.12 EPS for the current year.

Insider Activity at UroGen Pharma

In other news, General Counsel Jason Drew Smith sold 7,379 shares of the stock in a transaction on Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the completion of the sale, the general counsel now owns 26,468 shares in the company, valued at approximately $294,853.52. This represents a 21.80 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Mark Schoenberg sold 4,551 shares of the firm's stock in a transaction on Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $50,698.14. Following the completion of the sale, the insider now directly owns 145,666 shares of the company's stock, valued at $1,622,719.24. The trade was a 3.03 % decrease in their position. The disclosure for this sale can be found here. 5.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On UroGen Pharma

Several hedge funds have recently modified their holdings of the stock. KLP Kapitalforvaltning AS purchased a new stake in UroGen Pharma during the 4th quarter worth approximately $59,000. Lazard Asset Management LLC acquired a new stake in shares of UroGen Pharma during the fourth quarter worth $67,000. BNP Paribas Financial Markets grew its holdings in shares of UroGen Pharma by 221.8% during the third quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company's stock valued at $109,000 after buying an additional 5,890 shares during the last quarter. Aquatic Capital Management LLC acquired a new position in shares of UroGen Pharma in the 4th quarter valued at $101,000. Finally, Oppenheimer & Co. Inc. acquired a new stake in UroGen Pharma during the 4th quarter worth about $126,000. Institutional investors and hedge funds own 91.29% of the company's stock.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.